Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

The drugmaker delivered revenue and earnings beats thanks to continued momentum for sleep disorder drug Xyrem.

Jazz Pharmaceuticals Sings a Sweet Tune in Q2

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2019 Results - Earnings Call Transcript

Celgene

Health Insurance Innovations

Looking for bargains? You'll definitely want to check out these dirt-cheap healthcare stocks.

3 Incredibly Cheap Healthcare Stocks

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

Jazz Pharmaceuticals has been granted approval for its sleep therapeutic drug Sunosi, which it plans to release midyear.

Jazz Pharmaceuticals: A Growth Stock Trading At Value Prices

Pacira Pharmaceuticals

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

JAZZ or PCRX: Which Is the Better Value Stock Right Now?

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "

JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.

Jazz Pharmaceuticals Hits All the Right Notes in Q1

Jazz Pharmaceuticals, Inc. (JAZZ) CEO Bruce Cozadd on Q1 2019 Results - Earnings Call Transcript

Alexion Pharma

The U.S. Justice Department said Thursday that Jazz Pharmaceuticals PLC , Alexion Pharmaceuticals Inc.  and Lundbeck LLC have agreed to pay a combined $122.6 million to settle allegations that they paid kickbacks through co-pay assistance foundations for their own products.

Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz (JAZZ) Down 0.4% Since Last Earnings Report: Can It Rebound?

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

Amarin Corporation Plc

AstraZeneca

Ligand Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Exact Sciences

How many have you heard of? And what can we learn from their strong performances?

News for Jazz Pharmaceuticals Stock (JAZZ)